Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.

November 14, 2018 admin CEO Interview, Healthcare Comments Off on Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.
Alex Wasyl, CEO Nexien BioPharma

 

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

Alex Wasyl, CEO Nexien BioPharma

 

 

 

 

 

 

Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.




Related Articles

Newsmakers

Medicine Man Technologies (OTC: MDCL) Unveils its Largest Deal Yet with Entry into a Term Sheet to Acquire a Group of Dispensaries Operating under the Starbuds Brand

September 3, 2019 admin Newsmakers Comments Off on Medicine Man Technologies (OTC: MDCL) Unveils its Largest Deal Yet with Entry into a Term Sheet to Acquire a Group of Dispensaries Operating under the Starbuds Brand

– The Company’s addition of a group of five dispensaries will increase the retail footprint and regional coverage of the Company in Colorado- As part of the agreement, one of the original industry pioneers, Brian […]

CEO Interview

Medicine Man Technologies (OTC: MDCL) Fast Growing Revenues & Profits in Marijuana “Picks & Shovels”

December 7, 2018 admin CEO Interview Comments Off on Medicine Man Technologies (OTC: MDCL) Fast Growing Revenues & Profits in Marijuana “Picks & Shovels”

  Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of […]

Healthcare

FDA Grants Face-to-Face Meeting to Discuss CytoDyn’s (OTC: CYDY) 510(k) Application for ProstaGene(TM) Prognostic Test

June 24, 2019 admin Healthcare, Newsmakers Comments Off on FDA Grants Face-to-Face Meeting to Discuss CytoDyn’s (OTC: CYDY) 510(k) Application for ProstaGene(TM) Prognostic Test

VANCOUVER, Washington, June 24, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications today announced that […]